nVRT Wearable Device for Chronic Vertigo

About Otolith Labs

Otolith Labs is a privately-held, pre-revenue biotech company pioneering a novel, non-pharmacological treatment for chronic vertigo. Its core innovation is a headworn wearable that uses patented bone conduction signals (nVRT) to interact with the inner ear's vestibular system, aiming to provide immediate symptom relief. Backed by FDA Breakthrough Device Designation and over $20M in funding from investors including Mark Cuban, the company is conducting clinical studies to support a De Novo FDA submission. Otolith addresses a significant unmet need in a large patient population with limited treatment options.

Therapeutic Areas

Other Chronic Vertigo Drugs